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Germline MLH1 and MSH2 mutations are scarce in young colorectal cancer patients with negative family history of the disease. To
evaluate the contribution of germline MSH6 mutations to early-onset colorectal cancer, we have analysed peripheral blood of 38
patients diagnosed with this disease before 45 years of age and who presented no family history of hereditary nonpolyposis colorectal
cancer-related cancers. Blood samples from 108 healthy volunteers were analysed for those genetic alterations suspected to affect
the function of MSH6. Of the seven (18.4%) MSH6 alterations found, we have identified three novel germline mutations, one 8bp
deletion leading to a truncated protein and two missense mutations resulting in the substitution of amino acids belonging to different
polarity groups. High-frequency microsatellite instability was found in the patient with the MSH6 deletion, but not in the other 27
carcinomas analysed. No MLH1 promoter methylation was detected in tumour tissue. Our findings suggest that germline MSH6
mutations contribute to a subset of early-onset colorectal cancer. Further studies are warranted to understand the genetic and
environmental factors responsible for the variable penetration of MSH6 germline mutations, as well as to identify other causes of
early-onset colorectal cancer.
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Germline mutations in mismatch repair (MMR) genes (mostly in
MLH1 and MSH2) are associated with hereditary nonpolyposis
colorectal cancer (HNPCC), a highly penetrant autosomal-domi-
nant syndrome characterised by several affected individuals with
colorectal cancer (CRC) or extracolonic tumours of the endome-
trium, stomach, small bowel, ureter, renal pelvis, ovary, and
hepatobiliary tract (Lynch and de la Chapelle, 2003). Hereditary
nonpolyposis colorectal cancer accounts for about 3–5% of all
CRC, including a large proportion of those with a young age of
diagnosis, representing the most common hereditary colon cancer
syndrome (Petersen et al, 1999; Umar et al, 2004). Hereditary
nonpolyposis colorectal cancer carriers are usually heterozygous
for the mutant allele, retaining a functional copy of the gene that is
apparently sufficient for DNA repair (Parsons et al, 1993). A
subsequent somatic mutation, leading to inactivation of the wild-
type allele, results in a mutator cancer phenotype named ‘high-
frequency microsatellite instability’ (MSI-H), characterised by a
high rate of base substitutions, as well as small insertions and
deletions in mono- and dinucleotide repeats (Ionov et al, 1993).
High-frequency microsatellite instability phenotype has also been
reported in sporadic CRC (10–15%), but somatic mutations in
MMR genes are rare in these cases (Peltomaki et al, 1993;
Kuismanen et al, 2000; Kamory et al, 2003). MLH1 promoter
region methylation, leading to silencing of this gene, is an
alternative mechanism to mutation underlying MSI-H in sporadic
CRC (Toyota et al, 1999). Genetic testing for hereditary predis-
position is therefore critical for effective management of suspected
HNPCC kindreds (de la Chapelle, 2004; Lynch et al, 2004; Hampel
et al, 2005).
The identification of hereditary predisposition is not always easy
based on clinical and familial data. Some CRC patients are
diagnosed at a very young age, but do not show a family history of
cancer indicative of HNPCC. The relative contribution of
environmental and genetic factors for the development of the
disease in this subset of patients is unknown, but previous
investigations have shown that germline mutations in MLH1 and
MSH2 genes are scarce (Southey et al, 2005). MSH6 germline
mutations have been mostly observed in atypical HNPCC families
presenting a weaker family history, possibly caused by lower
penetrance of mutations in this gene (Hendriks et al, 2004;
Plaschke et al, 2004), and tumours in these families may be
‘microsatellite stable’, may present ‘low-frequency microsatellite
instability’ (MSI-L), or may be MSI-H (Wu et al, 1999; Plaschke
et al, 2000; Berends et al, 2002). We therefore aimed to evaluate the
contribution of germline MSH6 mutations for early-onset CRC in
patients without a family history of HNPCC-related cancer.
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Patients, samples, and DNA extraction
After written informed consent, DNA was isolated from
peripheral blood samples of 38 individuals who developed CRC
before the age of 45 years and had negative family history
of the disease (or other HNPCC-associated cancers; Table 1), using
the salt–chloroform extraction method (Mu ¨llenbach et al,
1989). DNA extraction was also performed from paraffin-
embedded tumours available from 28 of the patients (Lungu
et al, 1992), as well as from peripheral blood of 108 healthy
volunteers. The study was approved by the Institution Review
Board.
Screening for germline MSH6 mutations
DNA from the 38 CRC patients were screened for MSH6 mutations
by denaturing gradient gel electrophoresis (DGGE) using primers
and conditions described previously (Wu et al, 1999). Exon 1 and
the acceptor splice site of exon 10, as well as samples with
abnormal DGGE patterns, were analysed by direct sequencing in
an ABI PRISM 310 automatic sequencer using Big Dye Terminator
Chemistry (Applied Biosystems, Foster City, CA, USA), according
to the manufacturer’s recommendations. Whenever necessary,
exon 7 was resequenced using different set of primers to exclude or
confirm the presence of a polymorphism at the initial primer-
annealing site (Kolodner et al, 1999).
MSI analysis
Of the 38 cases, DNA from 28 paraffin-embedded tumours and
paired lymphocyte samples were evaluated for MSI. We analysed
the Bethesda marker panel (Boland et al, 1998), which includes two
mononucleotide repeats (BAT25 and BAT26) and three dinucleo-
tide repeats (D2S123, D5S346, and D17S250). Another three
mononucleotide repeat markers (BAT34C4, BAT-RII, and BAX)
were also analysed, as MSI in MSH6 carriers has been mainly
observed in this type of markers (Verma et al, 1999; Wijnen et al,
1999). DNA was amplified by PCR using fluorescence-labelled 50
primers, as described previously (Oliveira et al, 1998; Zhou et al,
1998; Pyatt et al, 1999; Loukola et al, 2001), and analysed in an ABI
PRISM 310 automatic sequencer. Cases were considered MSI-H
when X30% of the markers were positive. The MSI-H case (see
below) was routinely analysed for MLH1 and MSH2 germline
mutations, using multiplex ligation-dependent probe amplification
(MRC-Holland, Amsterdam), DGGE, and direct sequencing with
primers and conditions described previously (Wu et al, 1997,
1998), and no pathogenic mutation was detected in these two
genes.
MLH1 promoter methylation analysis
MLH1 promoter methylation status was evaluated in MSI-positive
cases (both MSI-H and MSI-L), using methylation-specific PCR
with primers and conditions described by Fleisher et al (2001).
RESULTS
Seven of the 38 patients (7/38; 18.4%) presented germline
MSH6 changes (Table 2), six of them not described previously.
One patient had the deletion c.3558_3565delTGAAAGTA
(p.G1186fsX1190), two patients presented the missense mutations
c.2633T4C (p.V878A) and c.3961A4G (p.R1321G), two patients
had the silent mutations c.2272C4T (p.L758L) and c.2319C4A








1 F 17 Ascending colon —
2 M 27 Ascending colon —
3 M 30 Rectum/sigmoid colon —
4 M 33 Sigmoid colon —
5 F 31 Sigmoid colon —
6 F 42 Rectum —
7 F 42 Rectum —
8 F 34 Rectum Father: lung cancer
9 M 19 Rectum —
10 F 40 Rectum —
11 F 38 Sigmoid colon —
12 M 36 Rectum Father: lung cancer
13 F 40 Rectum —
14 F 30 Rectum —
15 F 45 Rectum —
16 M 39 Rectum —
17 F 43 Rectum —
18 F 45 Sigmoid colon —
19 M 39 Rectum —
20 M 45 Rectum —
21 M 45 Ascending colon —
22 M 31 Rectum —
23 M 42 Rectum —
24 M 38 Ascending colon —
25 F 40 Rectum —
26 F 32 Ascending colon —
27 M 35 Rectum —
28 M 35 Rectum —
29 M 29 Sigmoid colon —
30 M 31 Rectum —
31 F 34 Rectum —
32 F 39 Rectum —
33 M 30 Rectum —
34 M 38 Sigmoid colon —
35 F 18 Rectum —
36 F 36 Rectum —
37 F 45 Rectum —
38 M 42 Rectum —
39 F 45 Rectum/sigmoid colon —
CRC¼colorectal cancer; F¼female; M¼male.
Table 2 MSH6 germline alterations (and respective MSI status) detected in 38 early-onset CRC patients and in healthy blood donors
Patient Exon/intron Nucleotide change
a Predicted effect MSI Blood donors
37 Exon 4 c.[648A4T; 649G4T]
b p.[T216T; D217Y] n.av. 0/108
25 Exon 4 c.2272C4T
b p.L758L n.av. n.an.
27 Exon 4 c.2319C4A
b p.L773L MSS n.an.
31 Exon 4 c.2633T4C p.V878A n.av. 2/108
15 Intron 5 c.3439-16C4T
b ? MSS 1/108
2 Exon 7 c.3558_3565delTGAAAGTA
b p.G1186fsX1190 MSI-H 1/108
14 Exon 9 c.3961A4G
b p.R1321G n.av. 0/108
CRC¼colorectal cancer; MSI¼microsatellite instability; MSI-H¼high-frequency microsatellite instability; MSS¼microsatellite stable; n.an.¼not analysed; n.av.¼not available.
aAccording to GenBank accession no. NM_000179, nucleotide numbering starts with the A of the start codon.
bNot described in the literature.
MSH6 mutations in early-onset colorectal cancer
C Pinto et al
753



















s(p.L773L), one patient showed the intronic alteration c.3439-
16C4T, and another patient had a silent mutation and a missense
mutation, c.[648A4T; 649G4T] (p.[T216T; D217Y]), in the same
allele (Table 2).
In cases in which changes were suspected to affect the function
of MSH6, namely, the deletion, the missense, and the intronic
alterations, we looked for these nucleotide changes in blood
samples from 108 healthy volunteers. The p.G1186fsX1190 and the
c.3439-16C4T alterations were detected once and p.V878A in
another two controls (Table 2). The p.G1186fsX1190 mutation was
initially detected in apparent homozygosity (Figure 1) in the CRC
patient and in the control using primers described by Wu et al
(1999). Direct sequencing with additional primers demonstrated
that these cases were in fact heterozygous for this mutation and
that an insertion polymorphism in intron 7 located in the primer-
annealing region had not allowed the amplification of one allele
with the initial set of primers (data not shown). The
p.G1186fsX1190 mutation was subsequently identified in the
healthy 54-year-old father of the proband (Figure 2).
High-frequency microsatellite instability and MSI-L was found
in one and two of the 28 tumours, respectively. The MSI-H patient
was positive only for the mononucleotide markers BAT25, BAT26,
and BATRII and presented the p.G1186fsX1190 mutation. The two
MSI-L patients were positive only for one marker and had no
germline mutations in the MSH6 gene. None of these three cases
showed MLH1 promoter hypermethylation in the tumour (data not
shown).
DISCUSSION
Molecular characterisation of early-onset CRC is important to
clarify whether this clinical feature is caused by dominant germline
mutations with variable penetrance or arising de novo, by recessive
inheritance, or are merely sporadic events. Two groups have
previously described one MSH6 germline mutation each in two
young CRC patients without family history of the disease (Chan























Figure 1 Possible disease-causing MSH6 mutations (arrows) identified in early-onset CRC patients. Denaturing gradient gel electrophoresis patterns and
the nucleotide sequences (reverse) are shown for cases 2 (A), 37 (B), and 14 (C). Negative control sequences are shown to the right.
MSH6 mutations in early-onset colorectal cancer
C Pinto et al
754



















sunreported MSH6 genetic alterations in 38 early-onset CRC
patients with negative family history of HNPCC-related cancer.
Three of these six alterations are novel MSH6 germline mutations
(three out of 38 mutations; 7.9%), namely, a deletion and two
missense mutations, one of the latter occurring contiguously to a
silent mutation (Figure 1).
The MSH6 mutation p.G1186fsX1190 is in all likelihood disease
causing, as it leads to a premature stop codon at position 1190 and
the predicted truncated protein looses one of the two MSH2- and
the Mg
2þ-binding domains (Kariola et al, 2002). In addition, the
patient’s tumour presented MSI-H phenotype only in mono-
nucleotide markers, a feature reported to occur preferentially in
tumours associated with MSH6 germline mutations (Verma et al,
1999; Wijnen et al, 1999), and screening for MLH1 and MSH2
mutations was negative. On the other hand, neither the 54-year-old
father (Figure 2) nor the 47-year-old healthy blood donor carrying
this mutation presented clinical symptoms of CRC (they had never
performed colonoscopy screening), suggesting variable penetrance
of this mutation. The modifier factors originating early-onset CRC
in this 27-year-old patient remain unknown, but some data suggest
that multiple mutations in different genes may influence the
penetrance of the disease (Scheenstra et al, 2003; Soravia et al,
2005; Okkels et al, 2006). For instance, Okkels et al (2006) reported
an 18-year-old CRC patient with three mutations (one missense
APC mutation and a nonsense and a missense MSH6 mutation),
whereas none of the family members presenting only one or two of
the three mutations presented colorectal neoplasms. Other authors
have suggested that genetic and environmental factors may modify
the risk conferred by mutations in cancer predisposition genes, as
considerable inter-individual variation in age at cancer diagnosis
has been observed in kindreds sharing the same genetic
predisposition mutation (Heinimann et al, 1999; Bala and
Peltomaki, 2001). Further studies are warranted to identify factors
modulating the age of onset, penetrance, or tumour location in
individuals with inherited MMR deficiency, as this knowledge may
improve risk estimates and help identify individuals who are
genetically susceptible to develop CRC at an early age.
The two missense mutations that were not detected in the
normal population (Figure 1) result in a substitution of amino
acids belonging to different polarity groups. The mutation
p.R1321G occurred in a highly conserved region of the gene, the
MSH2-binding domain, suggesting that it would affect MSH6
protein function. The p.[T216T; D217Y] mutation, although not
located in a functional domain, results in the substitution of a
negatively charged amino acid for a non-polar amino acid that
may cause abnormal MSH6 protein function. As these two
genomic alterations are likely to alter the function of the protein
and were not found in the control population, it is likely that they
are pathogenic mutations, but functional studies will be necessary
to determine how each of these MSH6 mutations affects protein
function.
Besides the three presumably pathogenic mutations, we also
identified three novel polymorphisms in the MSH6 gene: the two
silent mutations p.L758L and p.L773L and the intronic alteration
c.3439-16C4T. On the other hand, the missense mutation
p.V878A has previously been reported as a possible disease-
causing mutation by some investigators (Wijnen et al, 1999; ICG-
HNPCC database) and as a polymorphism by others (Peterlongo
et al, 2003). Our finding of this alteration in the normal population
corroborates that of Peterlongo et al (2003) and this change should
now be classified as a polymorphism.
Of the 28 tumours that could be studied, MSI-H was found only
in the case with MSH6 deletion. This tumour shows instability only
in mononucleotide repeats, that is consistent with the higher
incidence of MSI in this kind of markers in MSH6-deficient
tumours described in the literature (Verma et al, 1999; Wijnen
et al, 1999). The MSI-L phenotype has also been related to
germline MSH6 mutations (Verma et al, 1999; Wijnen et al, 1999),
but none of the two MSI-L tumours in this series showed MSH6
mutations or MLH1 promoter hypermethylation. The biological
basis of the MSI-L phenotype is currently under debate. This
phenotype could result from alterations in MMR proteins
other than MSH2 and MLH1, from defects in genes not directly
involved in MMR, or it could simply represent a ‘background’
level of genetic instability that may be detectable in all tumours
if a sufficient number of markers is analysed (Lengauer et al,
1998).
We conclude that germline MSH6 mutations contribute to a
subset of early-onset CRC patients without a family history of the
disease. Further studies are warranted to understand the genetic
and environmental factors responsible for the variable penetration
of these germline mutations and to identify other causes of early-
onset CRC, as this would help genetic counselling of these patients
and their relatives.
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